Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

[Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?]

Akyol Ardıç Ü, Ercan ES, Aygüneş D, Yüce D, Durak S, Kosova B.

Turk Psikiyatri Derg. 2017 Summer;28(2):89-94. Turkish.

2.

Specific Genes Associated with Adverse Events of Methylphenidate Use in the Pediatric Population: A Systematic Literature Review.

Joensen B, Meyer M, Aagaard L.

J Res Pharm Pract. 2017 Apr-Jun;6(2):65-72. doi: 10.4103/jrpp.JRPP_16_161. Review.

3.

Dopamine receptor DRD4 gene and stressful life events in persistent attention deficit hyperactivity disorder.

Sánchez-Mora C, Richarte V, Garcia-Martínez I, Pagerols M, Corrales M, Bosch R, Vidal R, Viladevall L, Casas M, Cormand B, Ramos-Quiroga JA, Ribasés M.

Am J Med Genet B Neuropsychiatr Genet. 2015 Sep;168(6):480-491. doi: 10.1002/ajmg.b.32340. Epub 2015 Jul 14.

PMID:
26174753
4.

Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.

Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, Gill M, Bellgrove MA, Hawi Z.

J Child Adolesc Psychopharmacol. 2013 Dec;23(10):655-64. doi: 10.1089/cap.2013.0032.

PMID:
24350812
5.

[Genetic bases of attention deficit hyperactivity disorder].

Sanchez-Mora C, Ribases M, Mulas F, Soutullo C, Sans A, Pamias M, Casas M, Ramos-Quiroga JA.

Rev Neurol. 2012 Nov 16;55(10):609-18. Review. Spanish.

6.

Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.

Bruxel EM, Salatino-Oliveira A, Genro JP, Zeni CP, Polanczyk GV, Chazan R, Rohde LA, Hutz MH.

Pharmacogenomics J. 2013 Oct;13(5):476-80. doi: 10.1038/tpj.2012.25. Epub 2012 Jun 12.

PMID:
22688218
7.

A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.

Walter Soria N, Belaus A, Galván C, Ana Pasquali M, Velez P, Del Carmen Montes C, Beltramo DM.

Genet Test Mol Biomarkers. 2010 Dec;14(6):749-51. doi: 10.1089/gtmb.2010.0037. Epub 2010 Sep 21.

PMID:
20858053
8.

Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.

Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS.

Toxicology. 2010 Apr 11;270(2-3):59-65. doi: 10.1016/j.tox.2010.01.009. Epub 2010 Jan 25.

PMID:
20097249
9.

Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.

Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M.

Neuropharmacology. 2009 Dec;57(7-8):731-3. doi: 10.1016/j.neuropharm.2009.08.014. Epub 2009 Sep 4.

PMID:
19733552
10.

Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1.

Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Hurley TD, Bosron WF.

J Pharmacol Exp Ther. 2004 Aug;310(2):469-76. Epub 2004 Apr 13.

Supplemental Content

Loading ...
Support Center